Pulse News Wire translates Japanese corporate disclosures filed with the Tokyo Stock Exchange's TDNet system into clear, structured English for institutional investors, hedge funds, and asset managers. Every article on this page is derived directly from an official TDNet filing â including earnings reports, M&A announcements, share buybacks, dividend declarations, and governance changes. Japanese corporate governance is governed by the Companies Act and the Financial Instruments and Exchange Act; timely translation of these disclosures provides a material information advantage for cross-border investors monitoring Tokyo-listed equities.
This corporate disclosure was processed by Pulse News Wire. It represents a primary source document for Japanese equity sector intelligence, translated directly from an official filing submitted to the Tokyo Stock Exchange TDNet system.
Source disclosure: March 02, 2026, 08:50 JST
Medrx Co.,Ltd. [4586.T]
TOKYO, Mar 02 (Pulse News Wire) â Medrx Co.,Ltd. (4586.T) released its earnings presentation for FY2025.
Revenue was ÂĨ122 million. For the full year, the company forecasts revenue of ÂĨ122 million.
AI-translated content. đĸ Confidence: High See terms âĸ Original filing
đŦ Help us improve translation quality
Notice any errors in this article? Let us know with one click.
â ī¸ Report an error
Please sig
đ Report 3+ errors with your email and get a free month of premium access
Report Error
Note: Financial figures from the earnings presentation have been removed pending correction. For accurate figures, refer to the company's earnings summary (kessan tanshin) filed separately on TDNet.
Know a colleague who covers Japanese equities? Forward them this article — they get 5 free translations to start.
